Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $80.00M to $0.00. Over 4 years (FY 2022 to FY 2026), Business Sale Proceeds shows a downward trend with a -10.4% CAGR.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
cf_proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $64.00M | $14.00M | $16.00M | $19.00M | $10.00M | $9.00M | $18.00M | $491.00M | $123.00M | $0.00 | -$23.00M | $0.00 | $0.00 | $43.00M | $54.00M | $80.00M | $2.00M | -$2.00M | $0.00 | $0.00 |
| QoQ Change | — | -78.1% | +14.3% | +18.8% | -47.4% | -10.0% | +100.0% | >999% | -74.9% | -100.0% | — | +100.0% | — | — | +25.6% | +48.1% | -97.5% | -200.0% | +100.0% | — |
| YoY Change | — | — | — | — | -84.4% | -35.7% | +12.5% | >999% | >999% | -100.0% | -227.8% | -100.0% | -100.0% | — | +334.8% | — | — | -104.7% | -100.0% | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.